CN107880029A - Design, synthesis and the application of a kind of indole derivatives antitumoral compounds containing pyrazol framework - Google Patents
Design, synthesis and the application of a kind of indole derivatives antitumoral compounds containing pyrazol framework Download PDFInfo
- Publication number
- CN107880029A CN107880029A CN201610877391.4A CN201610877391A CN107880029A CN 107880029 A CN107880029 A CN 107880029A CN 201610877391 A CN201610877391 A CN 201610877391A CN 107880029 A CN107880029 A CN 107880029A
- Authority
- CN
- China
- Prior art keywords
- compound
- reactant mixture
- structural formula
- reaction
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- FBYDJZXWEGXWIQ-UHFFFAOYSA-N Cc(cc1)ccc1-[n]1ncc(NC(c2c[nH]c3ccccc23)=O)c1 Chemical compound Cc(cc1)ccc1-[n]1ncc(NC(c2c[nH]c3ccccc23)=O)c1 FBYDJZXWEGXWIQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
The invention discloses indole derivatives of the one kind containing pyrazol framework, its preparation method and application, the structure of the indole derivatives containing pyrazol framework as shown in formula,Wherein, R1Selected from H, CH3；R2Selected from CH3、‑CH2CH3、
Description
Technical field
The invention belongs to medicinal chemistry art, more particularly to indole derivatives containing pyrazol framework, its preparation method and
Using.
Background technology
In recent years, with from cell, molecular level to the further understanding of Tumorigenesis, some produce in tumour and
The large biological molecule such as the key signal path and membrane receptor that are played a significant role in development, kinases is disclosed so that for this
A little efficient antineoplastics of tumor-specific molecule drone design low toxicity are possibly realized.Mitogen original activated protein kinase
(MAPK) signal transduction pathway is one of intracellular most important signal path, and BRAF is the key members in path MAPK, greatly
About 8% human tumor is found with V600E mutation BRAF (BRAFV600E), so as to cause downstream MEK-ERK signal paths to be held
Continuous abnormal activation, the growth, propagation, invasion and attack and transfer to tumour are most important.Therefore, BRAFV600EIt is current antineoplastic
The popular target of research and development.
High flux virtual screening technology is the screening technique being commonly used.High flux virtual screening technology is by target protein
The computational screening technology that high-resolution crystal structure is carried out as template.First, using high flux virtual screening technology with
BRAFV600EAlbumen is that template filter comes out molecule of the skeleton.Then, using Discovery Studio softwares by molecule of the skeleton and
BRAFV600EAlbumen carries out molecular docking, and corresponding modification transformation is carried out to it, obtains best molecule of the skeleton.
The content of the invention
It is an object of the invention to provide one kind to be used as BRAFV600EThe indoles containing pyrazol framework of target spot inhibitor derive
Thing, its preparation method and its application in tumour medicine.
Technical scheme：A kind of indole derivatives containing pyrazol framework, its structure as shown in formula,
Wherein, R1Selected from H ,-CH3；R2Selected from-CH3、-CH2CH3、
A kind of method for preparing the indole derivatives containing pyrazol framework, the indole derivatives containing pyrazol framework
Structure as shown in formula,
Wherein, R1Selected from H ,-CH3；R2Selected from-CH3、-CH2CH3、
Preparation method comprises the following steps,
Step 1. is dissolved into dry DMF (350mL) at 0 DEG C, by indole -3-carboxylic acid methyl ester (25.00g, 142.7mmol)
In, sodium hydride (60%, be stored in mineral oil, 8.26g, a 214mmol) part part is added to above-mentioned mixing
In thing.After all addition terminates sodium hydride, iodomethane (44.4mL, 713.5mmol) is added in solution, then will be whole
Reaction system is placed in stirring reaction 15 minutes in 0 DEG C, and reaction system finally is slowly ramped into room temperature, and stirring reaction is overnight.Treat
After reaction terminates, addition water is quenched in reaction solution.Obtained reactant mixture water and ethyl acetate (30mL × 3) extraction
Take, organic phase uses saturated aqueous common salt and washing successively, and is removed water organic phase using anhydrous magnesium sulfate.Finally, by organic phase
Vacuum decompression evaporation drying obtains crude product, and carries out separating-purifying to it using silica gel column chromatography, obtains structural formula as indicated at a
Compound.Appropriate potassium hydroxide is dissolved in water, then obtained compound A is added in above-mentioned solution, is added suitable
The methanol of amount, whole reaction system is then placed in stirring reaction 2 hours in 60 DEG C.After question response terminates, by reactant mixture
Vacuum decompression evaporation drying removes the methanol in reaction system, then adds dilute hydrochloric acid solution and adjusts Ph values to 5-6, has big
White solid is measured to separate out.The white solid of precipitation is separated by filtration, finally obtained solid is dried, obtains structural formula such as B institutes
The compound shown.
Pyrazoles (14g, 205.64mmol) is dissolved in the concentrated sulfuric acid (50mL), then by concentrated nitric acid by step 2. at 0 DEG C
(9.2Ml, 226.20mmol) is added dropwise, and adds after terminating whole reaction system temperature is heated slowly into 60 while stirring
℃.Whole reactant mixture agitating and heating is reacted into 1.5h.After question response terminates, reactant mixture is added to mixture of ice and water
In (600g).After standing a period of time, reactant mixture has white solid precipitation, is then separated by filtration white solid, will
The white solid separated is dried after washing again, obtains the compound of a part of structural formula as shown at c.By the filter after filtering
Liquid is extracted with ethyl acetate (100mL × 3), obtains organic phase.Sodium bicarbonate solution (100mL) of the organic phase with 1%, water
(100mL) and saturated aqueous common salt (100mL) rinse successively.Finally, the ethyl acetate anhydrous sodium sulfate drying after will be treated
And vacuum decompression evaporation drying obtains the compound of another part structural formula as shown at c.
Compound (7.14mmol), structural formula compound as shown atd of the step 3. by structural formula as shown at c
(7.14mmol), 8-hydroxyquinoline (0.18g, 1.23mmol), potassium carbonate (1.8g, 13.02mmol) are dissolved in anhydrous dimethyl Asia
In sulfone (9mL), the container where reactant mixture is then poured into argon gas, adds cuprous iodide (0.135g, 0.69mmol).
Whole reaction system is heated to 130 DEG C, then agitating and heating reaction 20h.Suitable quantity of water is added to reaction by question response after terminating
In system, a large amount of solids can be produced.Solid is separated by filtration and dries and separating-purifying is carried out to it using silica gel column chromatography, is obtained
Compound of the structural formula as shown in E.
Compound (4mmol) of the structural formula as shown in E is dissolved in absolute ethyl alcohol (4mL) by step 4., is then added
80% hydrazine hydrate solution (2mL), 10% palladium carbon hydrogenation catalyst (0.08g).Then the temperature of reactant mixture is heated
To 80 DEG C, reaction system is heated while stirring and reacted 10 minutes.After question response terminates, reactant mixture is filtered, collects filter
Liquid.Finally, filter vacuum is evaporated under reduced pressure and is dried to obtain compound of the structural formula as shown in F.
Step 5. is by compound (0.25mmol) of the structural formula as shown in B, EDC (0.25mmol), HOBT (0.25mmol)
It is dissolved in dry DMF (5mL), reactant mixture is then positioned over stirring reaction 30 minutes under normal temperature., will after 30 minutes
Compound (0.25mmol) of the structural formula as shown in F, DMAP (0.25mmol), triethylamine (1mL) are added in reactant mixture,
Then reaction is stayed overnight while stirring at normal temperatures for whole reaction.After question response terminates, obtained reactant mixture saturated common salt
Water and ethyl acetate (100mL × 3) extraction, finally, obtain crude product, and utilize silica gel by organic phase vacuum decompression evaporation drying
Column chromatography carries out separating-purifying to it, obtains compound of the final structural formula as shown in G.
In formula A~G, R1Selected from H ,-CH3；R2Selected from-CH3、-CH2CH3、
Embodiment
In some specific embodiment, the structural formula of preparation process of the invention and associated products is as described below：
A kind of method for preparing the above-mentioned indole derivatives containing pyrazol framework, it comprises the following steps：
Step 1. is dissolved into dry DMF (350mL) at 0 DEG C, by indole -3-carboxylic acid methyl ester (25.00g, 142.7mmol)
In, sodium hydride (60%, be stored in mineral oil, 8.26g, a 214mmol) part part is added to above-mentioned mixing
In thing.After all addition terminates sodium hydride, iodomethane (44.4mL, 713.5mmol) is added in solution, then will be whole
Reaction system is placed in stirring reaction 15 minutes in 0 DEG C, and reaction system finally is slowly ramped into room temperature, and stirring reaction is overnight.Treat
After reaction terminates, addition water is quenched in reaction solution.Obtained reactant mixture water and ethyl acetate (30mL × 3) extraction
Take, organic phase uses saturated aqueous common salt and washing successively, and is removed water organic phase using anhydrous magnesium sulfate.Finally, by organic phase
Vacuum decompression evaporation drying obtains crude product, and carries out separating-purifying to it using silica gel column chromatography, obtains structural formula as indicated at a
Compound.Appropriate potassium hydroxide is dissolved in water, then obtained compound A is added in above-mentioned solution, is added suitable
The methanol of amount, whole reaction system is then placed in stirring reaction 2 hours in 60 DEG C.After question response terminates, by reactant mixture
Vacuum decompression evaporation drying removes the methanol in reaction system, then adds dilute hydrochloric acid solution and adjusts ph values to 5-6, has big
White solid is measured to separate out.The white solid of precipitation is separated by filtration, finally obtained solid is dried, obtains structural formula such as B institutes
The compound shown.
Pyrazoles (14g, 205.64mmol) is dissolved in the concentrated sulfuric acid (50mL), then by concentrated nitric acid by step 2. at 0 DEG C
(9.2Ml, 226.20mmol) is added dropwise, and adds after terminating whole reaction system temperature is heated slowly into 60 while stirring
℃.Whole reactant mixture agitating and heating is reacted into 1.5h.After question response terminates, reactant mixture is added to mixture of ice and water
In (600g).After standing a period of time, reactant mixture has white solid precipitation, is then separated by filtration white solid, will
The white solid separated is dried after washing again, obtains the compound of a part of structural formula as shown at c.By the filter after filtering
Liquid is extracted with ethyl acetate (100mL × 3), obtains organic phase.Sodium bicarbonate solution (100mL) of the organic phase with 1%, water
(100mL) and saturated aqueous common salt (100mL) rinse successively.Finally, the ethyl acetate anhydrous sodium sulfate drying after will be treated
And vacuum decompression evaporation drying obtains the compound of another part structural formula as shown at c.
Compound (7.14mmol), structural formula compound as shown atd of the step 3. by structural formula as shown at c
(7.14mmol), 8-hydroxyquinoline (0.18g, 1.23mmol), potassium carbonate (1.8g, 13.02mmol) are dissolved in anhydrous dimethyl Asia
In sulfone (9mL), the container where reactant mixture is then poured into argon gas, adds cuprous iodide (0.135g, 0.69mmol).
Whole reaction system is heated to 130 DEG C, then agitating and heating reaction 20h.Suitable quantity of water is added to reaction by question response after terminating
In system, a large amount of solids can be produced.Solid is separated by filtration and dries and separating-purifying is carried out to it using silica gel column chromatography, is obtained
Compound of the structural formula as shown in E.
Compound (4mmol) of the structural formula as shown in E is dissolved in absolute ethyl alcohol (4mL) by step 4., is then added
80% hydrazine hydrate solution (2mL), 10% palladium carbon hydrogenation catalyst (0.08g).Then the temperature of reactant mixture is heated
To 80 DEG C, reaction system is heated while stirring and reacted 10 minutes.After question response terminates, reactant mixture is filtered, collects filter
Liquid.Finally, filter vacuum is evaporated under reduced pressure and is dried to obtain compound of the structural formula as shown in F.
Step 5. is by compound (0.25mmol) of the structural formula as shown in B, EDC (0.25mmol), HOBT (0.25mmol)
It is dissolved in dry DMF (5mL), reactant mixture is then positioned over stirring reaction 30 minutes under normal temperature., will after 30 minutes
Compound (0.25mmol) of the structural formula as shown in F, DMAP (0.25mmol), triethylamine (1mL) are added in reactant mixture,
Then reaction is stayed overnight while stirring at normal temperatures for whole reaction.After question response terminates, obtained reactant mixture saturated common salt
Water and ethyl acetate (100mL × 3) extraction, finally, obtain crude product, and utilize silica gel by organic phase vacuum decompression evaporation drying
Column chromatography carries out separating-purifying to it, obtains compound of the final structural formula as shown in G.
Embodiment one：N- (1- (4- methoxyphenyls) -1H- pyrazoles -4- bases) -1- Methyl-1H-indole -3- formamides
The preparation of (5a)
At 0 DEG C, indole -3-carboxylic acid methyl ester (25.00g, 142.7mmol) is dissolved into dry DMF (350mL), by hydrogen
Change being added in said mixture for sodium (60%, be stored in mineral oil, 8.26g, a 214mmol) part part.When
After sodium hydride whole addition terminates, iodomethane (44.4mL, 713.5mmol) is added in solution, then by whole reactant
System is placed in stirring reaction 15 minutes in 0 DEG C, reaction system finally is slowly ramped into room temperature, stirring reaction is overnight.Question response knot
Shu Hou, addition water is quenched in reaction solution.Obtained reactant mixture water and ethyl acetate (30mL × 3) extraction, has
Machine mutually uses saturated aqueous common salt and washing successively, and is removed water organic phase using anhydrous magnesium sulfate.Finally, organic phase vacuum is subtracted
Pressure evaporation drying obtains crude product, and carries out separating-purifying to it using silica gel column chromatography, obtains white solid.By appropriate hydrogen-oxygen
Change potassium to be dissolved in water, then obtained white solid is added in above-mentioned solution, adds appropriate methanol, then will be whole
Reaction system is placed in stirring reaction 2 hours in 60 DEG C.After question response terminates, reactant mixture vacuum decompression evaporation drying is removed
Methanol in reaction system, then add dilute hydrochloric acid solution and adjust ph values to 5-6, have a large amount of white solids and separate out.Will analysis
The white solid gone out is separated by filtration, and is finally dried obtained solid, is obtained compound 1a.At 0 DEG C, by pyrazoles (14g,
205.64mmol) it is dissolved in the concentrated sulfuric acid (50mL), then concentrated nitric acid (9.2Ml, 226.20mmol) is added dropwise, adds
Temperature is heated slowly to 60 DEG C by whole reaction system while stirring after end.Whole reactant mixture agitating and heating is reacted
1.5h.After question response terminates, reactant mixture is added in mixture of ice and water (600g).After standing a period of time, reaction is mixed
Compound has white solid precipitation, is then separated by filtration white solid, is dried after the white solid separated is washed again,
Obtain a part of compound 2a.Filtrate after filtering is extracted with ethyl acetate (100mL × 3), obtains organic phase.Organic
Mutually rinsed successively with 1% sodium bicarbonate solution (100mL), water (100mL) and saturated aqueous common salt (100mL).Finally, will handle
Later ethyl acetate obtains another part compound 2a with anhydrous sodium sulfate drying and vacuum decompression evaporation drying.It will change
Compound 2a (7.14mmol), to methoxyl group iodobenzene (7.14mmol), 8-hydroxyquinoline (0.18g, 1.23mmol), potassium carbonate
(1.8g, 13.02mmol) is dissolved in anhydrous dimethyl sulfoxide (9mL), and the container where reactant mixture then is poured into argon gas,
Add cuprous iodide (0.135g, 0.69mmol).Whole reaction system is heated to 130 DEG C, then agitating and heating is reacted
20h.Suitable quantity of water is added in reaction system by question response after terminating, and can produce a large amount of solids.Solid is separated by filtration and dried simultaneously
Separating-purifying is carried out to it using silica gel column chromatography, obtains compound 3a.Compound 3a (4mmol) is dissolved in absolute ethyl alcohol
In (4mL), 80% hydrazine hydrate solution (2mL), 10% palladium carbon hydrogenation catalyst (0.08g) are then added.Then will reaction
The temperature of mixture is heated to 80 DEG C, and reaction system is heated while stirring and reacted 10 minutes.It is after question response terminates, reaction is mixed
Compound filters, and collects filtrate.Finally, filter vacuum is evaporated under reduced pressure and is dried to obtain compound 4a.By compound 1a
(0.25mmol), EDC (0.25mmol), HOBT (0.25mmol) are dissolved in dry DMF (5mL), then by reactant mixture
It is positioned over stirring reaction 30 minutes under normal temperature.Is by compound 4a (0.25mmol), DMAP (0.25mmol), three after 30 minutes
Ethamine (1mL) is added in reactant mixture, and then reaction is stayed overnight while stirring at normal temperatures for whole reaction.Question response terminates
Afterwards, reactant mixture saturated aqueous common salt and ethyl acetate (100mL × 3) extraction obtained, finally, by organic phase vacuum decompression
Evaporation drying obtains crude product, and carries out separating-purifying to it using silica gel column chromatography, obtains final compound 5a.Obtain white
Color solid powder, yield 82.4%, m.p.236.5~238.7 DEG C；1H NMR(DMSO-d6, 400MHz) and δ：10.12 (s, 1H,
NH), 8.59 (s, 1H, ArH), 8.40-8.10 (m, 2H, CH), 7.78 (d, J=32.9Hz, 3H, ArH), 7.55 (d, J=
7.0Hz, 1H, CH), 7.44-6.79 (m, 4H, ArH), 3.85 (d, J=34.1Hz, 6H, CH3).MS EI+：346.39
(C20H18N4O2, [M]+).
Embodiment two：The preparation of N- (1- benzyl -1H- pyrazoles -4- bases) -1- Methyl-1H-indole -3- formamides (5b)
Preparation method reference implementation example one.Obtain white solid powder, yield 80.2%, m.p.191~192 DEG C；1H
NMR(DMSO-d6, 400MHz) and δ：9.98 (s, 1H, NH), 8.22 (d, J=7.9Hz, 1H, ArH), 8.13 (d, J=10.6Hz,
2H, CH), 7.63-7.48 (m, 2H, ArH), 7.39-7.22 (m, 6H, ArH), 7.19 (t, J=7.4Hz, 1H, CH), 5.32 (s,
2H, CH2), 3.87 (s, 3H, CH3).MS EI+：330.39(C20H18N4O, [M]+).
Embodiment three：The preparation of 1- methyl-N- (1- methyl isophthalic acid H- pyrazoles -4- bases) -1H- indoles -3- formamides (5c)
Preparation method reference implementation example one.Obtain white solid powder, yield 79.5%, m.p.190.2~192.7
℃；1H NMR(DMSO-d6, 400MHz) and δ：9.90 (s, 1H, NH), 8.22 (d, J=7.8Hz, 1H, ArH), 8.12 (s, 1H,
CH), 8.01 (s, 1H, CH), 7.52 (t, J=4.0Hz, 2H, ArH), 7.25 (t, J=7.5Hz, 1H, ArH), 7.19 (t, J=
7.4Hz, 1H, CH), 3.85 (d, J=17.4Hz, 6H, CH3).MS EI+：254.29(C14H14N4O, [M]+).
Example IV：The preparation of N- (1- ethyl -1H- pyrazoles -4- bases) -1- Methyl-1H-indole -3- formamides (5d)
Preparation method reference implementation example one.Obtain white solid powder, yield 84.6%, m.p.174.8~175.6
℃；1H NMR(DMSO-d6, 400MHz) and δ：9.91 (s, 1H, NH), 8.22 (d, J=7.7Hz, 1H, ArH), 8.12 (s.1H,
CH), 8.04 (s, 1H, CH), 7.52 (d, J=8.2Hz, 2H, ArH), 7.25 (t, J=7.5Hz, 1H, ArH), 7.19 (t, J=
7.4Hz, 1H, CH), 4.11 (q, J=7.2Hz, 2H, CH2), 3.87 (s, 3H, CH3), 1.37 (t, J=7.3Hz, 3H, CH3).MS
EI+：268.32(C15H16N4O, [M]+).
Embodiment five：The preparation of 1- methyl-N- (1- phenyl -1H- pyrazoles -4- bases) -1H- indoles -3- formamides (5e)
Preparation method reference implementation example one.Obtain white solid powder, yield 81.3%, m.p.182.4~184.4
℃；1H NMR(DMSO-d6, 400MHz) and δ：10.15 (s, 1H, NH), 8.69 (s, 1H, ArH), 8.26 (d, J=7.7Hz, 1H,
CH), 8.18 (s, 1H, CH), 7.88 (s, 1H, CH), 7.84 (d, J=7.9Hz, 2H, ArH), 7.56-7.48 (m, 3H, ArH),
7.29 (q, J=7.8Hz, 2H, ArH), 7.21 (t, J=7.4Hz, 1H, ArH), 3.90 (s, 3H, CH3).MS EI+：316.36
(C19H16N4O, [M]+).
Embodiment six：1- methyl-N- (1- (p-methylphenyl) -1H- pyrazoles -4- bases) -1H- indoles -3- formamides (5f)
Prepare
Preparation method reference implementation example one.Obtain white solid powder, yield 79.4%, m.p.180.8~183.2
℃；1H NMR(DMSO-d6, 400MHz) and δ：10.13 (s, 1H, NH), 8.64 (s, 1H, ArH), 8.25 (d, J=7.7Hz, 1H,
CH), 8.17 (s, 1H, CH), 7.84 (s, 1H, CH), 7.71 (d, J=8.4Hz, 2H, ArH), 7.32-7.18 (m, 5H, ArH),
3.89 (s, 3H, CH3), 2.34 (s, 3H, CH3).MS EI+：330.39(C20H18N4O, [M]+).
Embodiment seven：1-N- methyl-N- (1- (4- methyl-benzyls) -1H- pyrazoles -4- bases) -1H- indoles -3- formamides
The preparation of (5g)
Preparation method reference implementation example one.Obtain white solid powder, yield 83.2%, m.p.188.3~190.3
℃；1H NMR(DMSO-d6, 400MHz) and δ：9.94 (s, 1H, NH), 8.20 (d, J=7.8Hz, 1H, ArH), 8.10 (d, J=
7.9Hz, 2H, CH), 7.60-7.48 (m, 2H, ArH), 7.25 (t, J=7.4Hz, 1H, CH), 7.17 (s, 5H, ArH), 5.25
(s, 2H, CH2), 3.86 (s, 3H, CH3), 2.28 (s, 3H, CH3).MS EI+：344.42(C21H20N4O, [M]+).
Embodiment eight：N- (1- (4- isopropyl benzyls) -1H- pyrazoles -4- bases) -1- Methyl-1H-indole -3- formamides
The preparation of (5h)
Preparation method reference implementation example one.Obtain white solid powder, yield 84.7%, m.p.208.3~211 DEG C；1H NMR(DMSO-d6, 400MHz) and δ：9.94 (s, 1H, NH), 8.21 (d, J=7.5Hz, 1H, ArH), 8.11 (s, 2H, CH),
7.55 (d, J=4.7Hz, 1H, ArH), 7.52 (d, J=8.0Hz, 1H, CH), 7.22 (s, 6H, ArH), 5.26 (s, 2H, CH2),
3.86 (d, J=4.5Hz, 3H, CH3), 2.86 (d, J=5.6Hz, 1H, CH), 1.22-1.13 (m, 6H, CH3).MS EI+：
372.47(C23H24N4O, [M]+).
Embodiment nine：N- (1- (3- methoxyphenyls) -1H- pyrazoles -4- bases) -1- Methyl-1H-indole -3- formamides
The preparation of (5i)
Preparation method reference implementation example one.Obtain white solid powder, yield 79.4%, m.p.167.4~170 DEG C；1H NMR(DMSO-d6, 400MHz) and δ：10.15 (s, 1H, NH), 8.70 (s, 1H, ArH), 8.26 (d, J=7.7Hz, 1H, CH),
8.18 (s, 1H, CH), 7.87 (s, 1H, CH), 7.55 (d, J=8.1Hz, 1H, ArH), 7.45-7.38 (m, 3H, ArH), 7.27
(t, J=7.5Hz, 1H, ArH), 7.21 (t, J=7.4Hz, 1H, ArH), 6.87 (dt, J=5.5,2.9Hz, 1H, ArH), 3.87
(d, J=16.8Hz, 6H, CH3).MS EI+：346.39(C20H18N4O2, [M]+).
Embodiment ten：N- (1- (2- ((4- methoxyphenyls) amino) -2- oxoethyls) -1H- pyrazoles -4- bases) -1- first
The preparation of base -1H- indoles -3- formamides (5j)
Preparation method reference implementation example one.Obtain bright yellow solid powder, yield 71.5%, m.p.223~225 DEG C；1H NMR(DMSO-d6, 600MHz) and δ：10.16 (s, 1H, NH), 9.95 (s, 1H, NH), 8.23 (d, J=7.9Hz, 1H, ArH),
8.12 (s, 2H, CH), 7.60 (s, 1H, ArH), 7.53 (d, J=9.0Hz, 3H, ArH), 7.27-7.24 (m, 1H, ArH), 7.19
(t, J=7.4Hz, 1H, CH), 6.91 (d, J=9.1Hz, 2H, ArH), 4.97 (s, 2H, CH2), 3.88 (s, 3H, CH3), 3.73
(s, 3H, CH3).MS EI+：403.44(C22H21N5O3, [M]+).
Embodiment 11：N- (1- (2- ((3- methoxyphenyls) amino) -2- oxoethyls) -1H- pyrazoles -4- bases) -1-
The preparation of Methyl-1H-indole -3- formamides (5k)
Preparation method reference implementation example one.Obtain pink solid powder, yield 71.9%, m.p.217~219 DEG C；1H NMR(DMSO-d6, 600MHz) and δ：10.30 (s, 1H, NH), 9.95 (s, 1H, NH), 8.23 (d, J=7.9Hz, 1H, ArH),
8.13 (s, 2H, CH), 7.60 (s, 1H, ArH), 7.53 (d, J=8.2Hz, 1H, ArH), 7.33 (s, 1H, ArH), 7.25 (q, J
=8.7,8.2Hz, 2H, ArH), 7.19 (t, J=7.9Hz, 1H, CH), 7.13 (d, J=8.1Hz, 1H, ArH), 6.67 (d, J=
8.2Hz, 1H, ArH), 5.00 (s, 2H, CH2), 3.88 (s, 3H, CH3), 3.73 (s, 3H, CH3).MS EI+：403.44(C22H2]
N5O3, [M]+).
Embodiment 12：The preparation of N- (1- benzyl -1H- pyrazoles -4- bases) -1H- indoles -3- formamides (5l)
Preparation method reference implementation example one.Obtain white solid powder, yield 82.8%, m.p.221~224 DEG C；1H
NMR(DMSO-d6, 400MHz) and δ 11.68 (s, 1H, NH), 9.93 (s, 1H, NH), 8.20 (d, J=7.7Hz, 1H, ArH), 8.15
(d, J=2.9Hz, 1H, CH), 8.14 (s, 1H, CH), 7.58 (s, 1H, ArH), 7.46 (d, J=7.8Hz, 1H, ArH), 7.36
(t, J=7.2Hz, 2H, ArH), 7.29 (dd, J=15.9,7.1Hz, 3H, ArH), 7.16 (dt, J=18.6,7.0Hz, 2H,
ArH), 5.32 (s, 2H, CH2).MS EI+：316.36(C19H16N4O, [M]+).
Embodiment 13：The preparation of N- (1- methyl isophthalic acid H- pyrazoles -4- bases) -1H- indoles -3- formamides (5m)
Preparation method reference implementation example one.Obtain yellow solid powder, yield 74.3%, m.p.202~204 DEG C；1H
NMR(DMSO-d6, 600MHz) and δ：11.65 (s, 1H, NH), 9.87 (s, 1H, NH), 8.21 (d, J=7.8Hz, 1H, ArH),
8.16 (d, J=2.9Hz, 1H, CH), 8.01 (s, 1H, CH), 7.52 (s, 1H, ArH), 7.46 (d, J=8.0Hz, 1H, ArH),
7.18 (t, J=6.9Hz, 1H, ArH), 7.14 (t, J=7.4Hz, 1H, CH), 3.83 (s, 3H, CH3).MS EI+：240.27
(C13H12N4O, [M]+).
Embodiment 14：The preparation of N- (1- (p-methylphenyl) -1H- pyrazoles -4- bases) -1H- indoles -3- formamides (5n)
Preparation method reference implementation example one.Obtain white solid powder, yield 75%, m.p.217~219.5 DEG C；1H
NMR(DMSO-d6, 600MHz) and δ：11.72 (s, 1H, NH), 10.09 (s, 1H, NH), 8.65 (s, 1H, ArH), 8.25 (d, J=
7.7Hz, 1H, CH), 8.22 (s, 1H, CH), 7.85 (s, 1H, CH), 7.71 (d, J=8.4Hz, 2H, ArH), 7.49 (d, J=
8.2Hz, 1H, ArH), 7.30 (d, J=8.4Hz, 2H, ArH), 7.18 (dt, J=22.2,7.1Hz, 2H, ArH), 2.34 (s,
3H, CH3).MS EI+：316.36(C19H16N4O, [M]+).
Embodiment 15：The system of N- (1- (4- methoxyphenyls) -1H- pyrazoles -4- bases) -1H- indoles -3- formamides (5o)
It is standby
Preparation method reference implementation example one.Obtain pink solid powder, yield 74.8%, m.p.212~215 DEG C；1H NMR(DMSO-d6, 400MHz) and δ：11.72 (s, 1H, NH), 10.07 (s, 1H, NH), 8.59 (s, 1H, ArH), 8.27-8.19
(m, 2H, CH), 7.82 (s, 1H, ArH), 7.74 (d, J=9.0Hz, 2H, ArH), 7.49 (d, J=8.0Hz, 1H, CH), 7.23-
7.12 (m, 2H, ArH), 7.05 (d, J=9.1Hz, 2H, ArH), 3.80 (s, 3H, CH3).MS EI+：332.36(C19H16N4O2,
[M]+).
Embodiment 16：N- (1- (2- ((4- methoxyphenyls) amino) -2- oxoethyls) -1H- pyrazoles -4- bases) -1H-
The preparation of indoles -3- formamides (5p)
Preparation method reference implementation example one.Obtain white solid powder, yield 78.6%, m.p.268.5~271.5
℃；1H NMR(DMSO-d6, 600MHz) and δ：11.66 (s, 1H, NH), 10.16 (s, 1H, NH), 9.92 (s, 1H, NH), 8.22 (d,
J=7.8Hz, 1H, ArH), 8.17 (s, 1H, CH), 8.12 (s, 1H, CH), 7.60 (s, 1H, ArH), 7.52 (d, J=8.9Hz,
2H, ArH), 7.47 (d, J=8.0Hz, 1H, ArH), 7.19 (t, J=7.4Hz, 1H, CH), 7.14 (t, J=7.4Hz, 1H,
ArH), 6.91 (d, J=8.9Hz, 2H, ArH), 4.97 (s, 2H, CH2), 3.73 (s, 3H, CH3).MS EI+：389.42
(C21H19N5O3, [M]+).
Embodiment 17：The Anticancer Activity in vitro progress of indole derivatives containing pyrazol framework
Bone containing pyrazoles is determined using MTT [3- (4,5)-bis- methyl -2- thiazoles-(2,5)-phenyl bromination tetrazole is blue] methods
The indole derivatives of frame are to Human colorectal cancer cells (HT-29), and people's malignant melanoma cell (A375), Humanmachine tumour is thin
The inhibiting rate of born of the same parents' (WM1361 cells) reaches drug concentration (half maximal inhibitory when 50%
Concentration, IC50)。
(1) preparation of nutrient solution：DMEM (basal medium) 89%, hyclone 10%, Penicillin Streptomycin Solution
(10000IU/mL, 10000 μ g/mL) 1%.
The culture of (2) three kinds of adherent cancer cells：Using above-mentioned nutrient solution, (nutrient solution volume is about the 1/ of blake bottle capacity
10), at 37 DEG C, 5%CO2Cultivated in incubator, judge the generation time according to the growth conditions of cancer cell.
(3) preparation of various concentrations medicine：Storing solution, every hole after dosing are prepared using tri-distilled water (a small amount of DMSO hydrotropies)
DMSO final concentration is usually no more than 0.05%-0.1% in cell suspension；Storing solution is diluted to four concentration ladders with tri-distilled water
Spend (100 μm of ol, 10 μm of ol, 1 μm of ol, 0.1 μm of ol)；It is stored in standby in -20 DEG C of refrigerators.
(4) cell incubation：Take the logarithm growth period tumour cell, tune concentration of cell suspension is 1-1.5 × 105/mL, after mixing
(100 μ L/ holes) is added in 96 well culture plates, at 37 DEG C, 5%CO224h is cultivated in incubator.
(5) dosing：The medicine of the various concentrations gradient diluted is added separately in 96 well culture plates, each concentration ladder
Degree sets 3 flat hole, continues to cultivate 48h.Experiment is divided into experimental group (nutrient solution, cell, medicine), control group (nutrient solution and cell)
With blank group (only nutrient solution).
(6) survivaling cell detects：In 96 orifice plates after having cultivated 48h, add the μ L/ holes of MTT (5mg/mL) 10；Put at 37 DEG C
After putting 4h, supernatant is removed, adds the μ L/ holes of DMSO 150, vibrated to formazan and crystallize all dissolvings；Existed using automatic ELIASA
The optical density (OD values) in each hole is detected at 570nm wavelength.
The calculating of inhibiting rate：
Growth inhibition ratio=(1- survival rates) × 100%=[1- (OD experiment-OD blank)/(OD control-OD blank)] ×
100% (OD experiments represent the average optical density of experimental group, and OD controls represent the average optical density of control group, and OD blank represents empty
The average optical density organized in vain).
According to the standard curve of drug concentration-inhibitory rate of cell growth, its IC is sought50。
Suppression IC of the listed indole derivatives containing pyrazol framework to tumour cell of the invention50Value (μm ol/mL) is seen below
Table
It was found from above-mentioned experiment：The present invention is to Human colorectal cancer cells (HT-29), people's malignant melanoma cell
(A375), human melanoma cell (WM1361 cells) has obvious inhibitory action, and activity is preferably.
Embodiment 18：The external evoked apoptosis recent progress in experimental study of indole derivatives containing pyrazol framework
The indole derivatives containing pyrazol framework are detected to HT-29 cells using the double dye methods of Annexin V-FITC/PI
Apoptosis is tested.
(1) suspension cell centrifugation (2000rpm centrifuges 5min) is collected；Attached cell uses the pancreatin digestion without EDTA to receive
Collection；
(2) wash cell secondary (2000rpm centrifuges 5min) with PBS and collect cell；
(3) 500 μ L Binding Buffer suspension cells are added；
(4) after adding 5 μ L Annexin V-FITC mixings, 5 μ L PI is added, is mixed；
(5) room temperature, lucifuge, reaction 5 to 15min；
(6) in one hour, the observation and detection of flow cytometer are carried out.
The listed indole derivatives containing pyrazol framework of the invention are to tumor cell induction apoptosis as in Figure of description
Shown in Fig. 1, Fig. 2.
It was found from above-mentioned experiment：The present invention has the work of obvious inducing cell apoptosis to Human colorectal cancer cells (HT-29)
With activity is preferably.
The preferred embodiment of the present invention described in detail above, still, the present invention are not limited in above-mentioned embodiment
Detail, in the range of the technology design of the present invention, a variety of equivalents can be carried out to technical scheme, this
A little equivalents belong to protection scope of the present invention.It is further to note that described in above-mentioned embodiment
Each particular technique feature, in the case of reconcilable, can be combined by any suitable means.In order to avoid not
Necessary repetition, the present invention no longer separately illustrate to various combinations of possible ways.In addition, a variety of implementations of the present invention
It can also be combined between mode, as long as it without prejudice to the thought of the present invention, it is public that it should equally be considered as institute of the invention
The content opened.
Brief description of the drawings
Fig. 1, the medicine are to the concentration dependant figure of HT-29 cells apoptosis
Fig. 2, the medicine are to the Time Dependent figure of HT-29 cells apoptosis.
Claims (4)
1. a kind of indole derivatives containing pyrazol framework, its structure as shown in formula,
Wherein, R1Selected from H ,-CH3；R2Selected from-CH3、-CH2CH3、
2. a kind of method for preparing the indole derivatives containing pyrazol framework, the knot of the indole derivatives containing pyrazol framework
Structure as shown in formula,
Wherein, R1Selected from H ,-CH3；R2Selected from-CH3、-CH2CH3、
Preparation method comprises the following steps,
Indole -3-carboxylic acid methyl ester (25.00g, 142.7mmol) is dissolved into dry DMF (350mL) by step 1. at 0 DEG C, will
Sodium hydride (60%, be stored in mineral oil, 8.26g, a 214mmol) part part is added in said mixture.
After all addition terminates sodium hydride, iodomethane (44.4mL, 713.5mmol) is added in solution, then will entirely be reacted
System is placed in stirring reaction 15 minutes in 0 DEG C, and reaction system finally is slowly ramped into room temperature, and stirring reaction is overnight.Question response
After end, addition water is quenched in reaction solution.Obtained reactant mixture water and ethyl acetate (30mL × 3) extraction,
Organic phase uses saturated aqueous common salt and washing successively, and is removed water organic phase using anhydrous magnesium sulfate.Finally, by organic phase vacuum
Reduction vaporization is dried to obtain crude product, and carries out separating-purifying to it using silica gel column chromatography, obtains the change of structural formula as indicated at a
Compound.Appropriate potassium hydroxide is dissolved in water, then obtained compound A is added in above-mentioned solution, added appropriate
Methanol, whole reaction system is then placed in stirring reaction 2 hours in 60 DEG C.After question response terminates, by reactant mixture vacuum
The methanol dried and removed in reaction system is evaporated under reduced pressure, then adds dilute hydrochloric acid solution and adjusts ph values to 5-6, has a large amount of white
Color solid separates out.The white solid of precipitation is separated by filtration, finally obtained solid is dried, obtains structural formula as shown in B
Compound.
Pyrazoles (14g, 205.64mmol) is dissolved in the concentrated sulfuric acid (50mL), then by concentrated nitric acid by step 2. at 0 DEG C
(9.2mL, 226.20mmol) is added dropwise, and adds after terminating whole reaction system temperature is heated slowly into 60 while stirring
℃.Whole reactant mixture agitating and heating is reacted into 1.5h.After question response terminates, reactant mixture is added to mixture of ice and water
In (600g).After standing a period of time, reactant mixture has white solid precipitation, is then separated by filtration white solid, will
The white solid separated is dried after washing again, obtains the compound of a part of structural formula as shown at c.By the filter after filtering
Liquid is extracted with ethyl acetate (100mL × 3), obtains organic phase.Sodium bicarbonate solution (100mL) of the organic phase with 1%, water
(100mL) and saturated aqueous common salt (100mL) rinse successively.Finally, the ethyl acetate anhydrous sodium sulfate drying after will be treated
And vacuum decompression evaporation drying obtains the compound of another part structural formula as shown at c.
Step 3. by structural formula compound (7.14mmol) as shown at c, structural formula compound (7.14mmol) as shown atd,
8-hydroxyquinoline (0.18g, 1.23mmol), potassium carbonate (1.8g, 13.02mmol) are dissolved in anhydrous dimethyl sulfoxide (9mL), so
The container where reactant mixture is poured into argon gas afterwards, adds cuprous iodide (0.135g, 0.69mmol).By whole reactant
System is heated to 130 DEG C, then agitating and heating reaction 20h.Suitable quantity of water is added in reaction system by question response after terminating, and can be produced
A large amount of solids.Solid is separated by filtration and dries and separating-purifying is carried out to it using silica gel column chromatography, obtains structural formula as shown in E
Compound.
Compound (4mmol) of the structural formula as shown in E is dissolved in absolute ethyl alcohol (4mL) by step 4., then adds 80%
Hydrazine hydrate solution (2mL), 10% palladium carbon hydrogenation catalyst (0.08g).Then the temperature of reactant mixture is heated to 80 DEG C,
Reaction system is heated while stirring and reacted 10 minutes.After question response terminates, reactant mixture is filtered, collects filtrate.Finally,
Filter vacuum is evaporated under reduced pressure and is dried to obtain compound of the structural formula as shown in F.
Step 5. dissolves compound (0.25mmol) of the structural formula as shown in B, EDC (0.25mmol), HOBT (0.25mmol)
In dry DMF (5mL), reactant mixture is then positioned over stirring reaction 30 minutes under normal temperature.After 30 minutes, by structure
Compound (0.25mmol) of the formula as shown in F, DMAP (0.25mmol), triethylamine (1mL) are added in reactant mixture, then
Whole reaction reaction while stirring at normal temperatures is overnight.After question response terminates, obtained reactant mixture saturated aqueous common salt and
Ethyl acetate (100mL × 3) extracts, and finally, organic phase vacuum decompression evaporation drying is obtained into crude product, and utilize silica gel column layer
Analysis carries out separating-purifying to it, obtains compound of the final structural formula as shown in G.
Wherein, R1Selected from H ,-CH3；R2Selected from-CH3、-CH2CH3、
3. application of the indole derivatives containing pyrazol framework in cancer therapy drug is prepared, it is characterised in that its structure such as formula institute
Show
Wherein, R1Selected from H ,-CH3；R2Selected from-CH3、-CH2CH3、
A kind of 4. cancer therapy drug, it is characterised in that including compound of the structure as shown in formula and medically acceptable carrier,
Wherein, R1Selected from H ,-CH3；R2Selected from-CH3、-CH2CH3、
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610877391.4A CN107880029A (en) | 2016-09-30 | 2016-09-30 | Design, synthesis and the application of a kind of indole derivatives antitumoral compounds containing pyrazol framework |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610877391.4A CN107880029A (en) | 2016-09-30 | 2016-09-30 | Design, synthesis and the application of a kind of indole derivatives antitumoral compounds containing pyrazol framework |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107880029A true CN107880029A (en) | 2018-04-06 |
Family
ID=61770168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610877391.4A Pending CN107880029A (en) | 2016-09-30 | 2016-09-30 | Design, synthesis and the application of a kind of indole derivatives antitumoral compounds containing pyrazol framework |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107880029A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111100116A (en) * | 2019-11-14 | 2020-05-05 | 南京大学 | Preparation method and application of novel aniline derivative containing methylindole and taking pyrazoline as skeleton |
| WO2022251533A1 (en) * | 2021-05-27 | 2022-12-01 | Protego Biopharma, Inc. | Heteroaryl diamide ire1/xbp1s activators |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008007113A2 (en) * | 2006-07-14 | 2008-01-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| WO2008079277A1 (en) * | 2006-12-22 | 2008-07-03 | Millennium Pharmaceuticals, Inc. | Certain pyrazoline derivatives with kinase inhibitory activity |
| CN102015639A (en) * | 2008-05-07 | 2011-04-13 | 医学研究委员会 | Compounds for use in stabilizing p53 mutants |
-
2016
- 2016-09-30 CN CN201610877391.4A patent/CN107880029A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008007113A2 (en) * | 2006-07-14 | 2008-01-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| WO2008079277A1 (en) * | 2006-12-22 | 2008-07-03 | Millennium Pharmaceuticals, Inc. | Certain pyrazoline derivatives with kinase inhibitory activity |
| CN102015639A (en) * | 2008-05-07 | 2011-04-13 | 医学研究委员会 | Compounds for use in stabilizing p53 mutants |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111100116A (en) * | 2019-11-14 | 2020-05-05 | 南京大学 | Preparation method and application of novel aniline derivative containing methylindole and taking pyrazoline as skeleton |
| WO2022251533A1 (en) * | 2021-05-27 | 2022-12-01 | Protego Biopharma, Inc. | Heteroaryl diamide ire1/xbp1s activators |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108969770B (en) | Dipeptide modified 1-methyl-3-hydroxymethyl-tetrahydro-beta-carboline, synthesis and application thereof | |
| CN109293657B (en) | Alpha-carboline ketone compound and preparation method and application thereof | |
| CN102746210A (en) | Synthesis method for key intermediate of silodosin | |
| CN107880029A (en) | Design, synthesis and the application of a kind of indole derivatives antitumoral compounds containing pyrazol framework | |
| CN109180625A (en) | A kind of preparation method of seleno flavone compound | |
| CN104402793A (en) | 3-substituted oxindole derivatives, and synthetic method and application thereof | |
| CN109824664A (en) | One group of antitumor indoles alkaloid compound and its preparation method and application | |
| CN110128343A (en) | A kind of hydrazide kind compound | |
| CN110511214A (en) | Two amidos replace heteroaromatic class compound and its preparation method and application | |
| CN106478692B (en) | Using 1 (2 pyridine) 9 benzyl β carbolines as the copper-nitrate complex and its synthetic method of part and application | |
| CN107903248A (en) | The Isatine derivatives of N substitution isatin heterozygosis quinazoline compounds synthesis and the application in antitumor drug is prepared | |
| CN105367483B (en) | The preparation method of Doneppezil Hydrochloride | |
| CN106632420A (en) | Copper chloride complex by taking 1-(2-pyridine)-9-butyl-beta-carboline as ligand as well as synthetic method and application of complex | |
| CN106632421A (en) | Copper nitrate complex of 1-(2-pyridine)-9-(4-methylbenzyl)-beta-carboline and synthesizing method and application of copper nitrate complex | |
| CN103588758A (en) | Synthesis and preparation of nitroimidazole derivative containing 1,4-benzdioxan skeleton and application of nitroimidazole derivative in anticancer drugs | |
| CN104211693B (en) | Rivaroxaban crystalline form, preparation method and application | |
| CN107118157A (en) | The design and synthesis of diphenyl urea analog derivative antitumoral compounds of one class containing pyrazol framework | |
| CN108864089B (en) | Indolopyridone drug molecule and preparation method and application thereof | |
| CN102268003B (en) | Unsymmetrical poly-substituted porphyrin gold (III) type anticancer compound and preparation method thereof | |
| CN109734677A (en) | The small molecule compound and its application of inhibition of histone lysine methyltransferase NSD2 | |
| CN104230786B (en) | Indole-structure-containing compound with anti-tumor activity and synthesis method thereof | |
| CN103044326A (en) | 5-bromo oxoisoaporphine, and synthesis method and application thereof | |
| CN108191764B (en) | Synthesis method of 1, 3-diaryl-1, 5,6, 7-tetrahydroindazole derivative | |
| CN107098861A (en) | Design, the synthesis of benzamide anti-tumor compounds of one class containing pyrazole ring | |
| CN106928224B (en) | Indoles Sophoridine derivative and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180406 |